Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

Frances Seymour, MRCP, BSc, MBBS, Mary H Young, PhD, Mark Tometsko, BSc, Jamie Cavenagh, MD PhD, Ethan G. Thompson, PhD, Elizabeth Whalen, PhD, Sam A Danziger, Alison Fitch, Brian A. Fox, PhD, Andrew Dervan, Teri Foy, PhD, Katie Newhall, PhD, John G. Gribben

Blood (2018) 132 (Supplement 1): 3296.

https://doi.org/10.1182/blood-2018-99-114453

Published: 2018

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Richard Dillon, MA, PhD MRCP, FRCPath, Robert K. Hills, MA, DPhil, MSc, Sylvie D Freeman, MBChB, DPhil, Nicola Potter, PhD, Adam Ivey, BSc, MSc, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Laura Upton, Asim Khwaja, MD PhD, Jamie Cavenagh, MD PhD, Ruth Spearing, MD, Alan K. Burnett, MD, Nigel H. Russell, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2018-99-113662

Published: 2018

Journal Articles

Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance

Frances Seymour, MRCP, BSc, MBBS, Jamie Cavenagh, MD PhD, John G. Gribben

Blood (2018) 132 (Supplement 1): 58.

https://doi.org/10.1182/blood-2018-99-114102

Published: 2018

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

A Phase II Study To Assess the Safety, Efficacy and Tolerability of Rituximab in Combination with Plasma Exchange in Patients with Acute Idiopathic Thrombotic Thrombocytopenic Purpura.

Marie Scully, MD, Jamie Cavenagh, MD, Beverley Hunt, MD, Hannah Cohen, MD, Samuel J. Machin, MD

Blood (2007) 110 (11): 1303.

https://doi.org/10.1182/blood.V110.11.1303.1303

Published: 2007

Journal Articles

The South East England Thrombotic Thrombocytopenic Purpura Registry.

Marie Scully, MD, Helen Yarranton, MD, Ri Liesner, MD, Jamie Cavenagh, MD, Beverley Hunt, MD, Sylvia Benjamin, MD, Michael Laffan, MD, David Bevan, MD, Ian Mackie, PhD, Samuel J. Machin, MD

Blood (2006) 108 (11): 1064.

https://doi.org/10.1182/blood.V108.11.1064.1064

Published: 2006

NARROW

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

A Phase II Study To Assess the Safety, Efficacy and Tolerability of Rituximab in Combination with Plasma Exchange in Patients with Acute Idiopathic Thrombotic Thrombocytopenic Purpura.

The South East England Thrombotic Thrombocytopenic Purpura Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only